環亞國際醫療科技集團有限公司 (香港聯交所上市編號: 1143)
公司用戶
行業 : 其他公司類型
1000人
N/A
N/A
N/A
Link-Asia International MedTech Group Limited (Stock Code: 01143.HK) (the “Group”), headquartered in Hong Kong, China, has such three major business sectors as electronics manufacturing services, real estate supply chain services and assisted reproductive services. Since 2020, the Group has started to focus its cross-border services on the layout of assisted reproductive industry chain. For such purpose, the Group has established several relevant subsidiaries, including: Link-Asia International Assisted Reproductive Technology Group Limited, Link-Asia International Cell Technology Group Limited, Link-Asia Medtech Investment Limited, etc.
The Group plans to provide the systematic solutions to those customers who has the intention to improve their fertility quality, by collaborating with the world leading assisted reproductive medical experts and organizations, reserving assisted reproductive medical technology, and interlinking domestic and overseas medical institutions such as testing labs, outpatient services, hospitals, etc. In the first half of 2021, the Group had signed the investment memos with I.Baby ARS & Eugenics, Nanjing Jilang Biotechnology, etc. successively, and formally entered into the Joint Venture Agreement with Hanguang Technology. The Group will continuously introduce the favorable resources in the relevant fields, in order to further solidify the layout of bio-industry chain that focuses on the assisted reproductive services and technology.
In the future, the Group will build such assisted reproduction service and technology value chain with full cycle, high carefulness and high quality, backed by the state-of-the-art assisted reproductive technology, in order to develop itself to be an influential group with certain scale in assisted reproductive service and technology industry within AP regions, the innovation led life science company, and the health management platform with the full-fertility cycle service in place, facilitating to develop the Healthy China and driving the industrial growth.